Novel Platform of Human Respiratory Tract

In an effort to face the challenges posed by infectious diseases affecting respiratory tracts, we have developed comprehensive and personalized virology platforms for risk assessment and evaluation of therapeutic strategies.

• Risk assessment of newly emerging respiratory viruses through in vitro, in vivo and ex vivo assays specific for influenza viruses and coronaviruses.
• Development of viral infected ex-vivo and organoid models for various respiratory viruses (influenza viruses and coronaviruses) to help evaluate the efficacity of antiviral drugs and compounds, and Respiratory Organoid Platform (ROP) for personalized risk assessment.
• Offering platforms for testing diagnostics, therapeutics, antiviral products, and vaccines as well as personalized platforms of human respiratory tract.

• The technology developed offers performant risk assessment through noninvasive procedure. A simple nose swab can predict infectivity of emerging respiratory viruses and host response as well as evaluate treatment responses and the development of personalized medicine.
• The development of personalized platforms initiates the next generation of public health strategies through precision medicine.
• Risk assessment by in vitro, in vivo and ex vivo assays and development of ex-vivo and organoid models offer a vast array of strategies and flexibility in patient care.

• Public Health Management
• Clinical application

• Patents filed